Blog
RSS FeedPosted by Michael Wonder on 25 Sep 2018
Alnylam Pharmaceuticals receives priority review in Canada for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
24 September 2018 - Health Canada grants priority review to promising medicines intended for the treatment of serious, debilitating or life-threatening ...
Posted by Michael Wonder on 21 Sep 2018
Health Canada has authorised Takhyzro (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema attacks
20 September 2018 - New treatment option for HAE receives first international marketing authorization outside of the U.S. ...
Posted by Michael Wonder on 20 Sep 2018
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of adults with previously treated advanced renal cell carcinoma
19 September 2018 - Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus ...
Posted by Michael Wonder on 19 Sep 2018
Sunovion announces Health Canada approval of Aptiom (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents and children above six years of age
19 September 2018 - Sunovion Pharmaceuticals today announced that Health Canada approved the supplemental new drug submission to expand the ...
Posted by Michael Wonder on 15 Sep 2018
Herceptin (trastuzumab) subcutaneous formulation approved in Canada for the treatment of HER2-positive breast cancer
13 September 2018 - Subcutaneous formulation takes two to five minutes to administer, rather than up to 90 minutes with the ...
Posted by Michael Wonder on 12 Sep 2018
Sunovion announces Health Canada acceptance of new drug submission for apomorphine sublingual film (APL-130277)
12 September 2018 - Sunovion seeks approval for apomorphine sublingual film for the on-demand treatment of OFF episodes associated with Parkinson’s ...
Posted by Michael Wonder on 12 Sep 2018
Health Canada approves Merck's Stromectol (ivermectin) for the treatment of intestinal strongyloidiasis and onchocerciasis
11 September 2018 - The product's availability is expected in November 2018. ...
Posted by Michael Wonder on 11 Sep 2018
Cipher Pharmaceuticals receives Health Canada approval of Xydalba (dalbavancin hydrochloride)
10 September 2018 - Cipher Pharmaceuticals today announced it received Health Canada approval of Xydalba (dalbavancin hydrochloride), the first and ...
Posted by Michael Wonder on 07 Sep 2018
Monoferric (iron isomaltoside 1000 for injection) receives marketing approval from Health Canada
6 September 2018 - Pharmacosmos is delighted to announce that marketing approval has been granted for Monoferric (global brand name Monofer) ...
Posted by Michael Wonder on 07 Sep 2018
Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
6 September 2018 - Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory ...
Posted by Michael Wonder on 05 Sep 2018
Baxter announces Health Canada approval of Olimel 7.6% high protein parenteral nutrition formulations
4 September 2018 - Highest protein and lowest glucose formulation among parenteral nutrition products (with or without electrolytes) available in a ...
Posted by Michael Wonder on 05 Sep 2018
Health Canada approves Perjeta (pertuzumab) for the treatment of HER2 positive early breast cancer after surgery
4 September 2018 - New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning ...
Posted by Michael Wonder on 03 Sep 2018
Emergency EpiPen alternative priced for Canadian market at $170 each
1 September 2018 - Health Minister has ordered Auvi-Q auto-injectors from the U.S. amid EpiPen shortage. ...
Posted by Michael Wonder on 30 Aug 2018
Health minister set to make U.S. made EpiPen alternative available in Canada
29 August 2018 - The federal government says an alternative to EpiPens will be available next month for Canadians with ...
Posted by Michael Wonder on 21 Aug 2018
Canada approves Daewoong Pharmaceutical’s BTX Nabota
20 August 2018 - South Korea’s Daewoong Pharmaceutical said Monday that Health Canada had granted marketing approval for its type ...